1. Introduction {#sec1}
===============

Systemic sclerosis (SSc) is an uncommon generalized connective tissue disorder with a broad spectrum of clinical diseases. Subtypes of the disease include diffuse cutaneous systemic sclerosis (dcSSc), limited cutaneous systemic sclerosis (lcSSc), systemic sclerosis sine scleroderma (ssSSc), and overlap disease. There are numerous autoantibodies associated with the disease, each of which can have important prognostic and phenotypic associations. One such autoantibody is anti-RNA polymerase III (anti-RNAP III). This specific autoantibody has been associated with diffuse cutaneous disease, scleroderma renal crisis, a temporal relationship with malignancy, myositis, synovitis, joint contractures, and gastric antral vascular ectasia \[[@B1], [@B2]\]. However, anti-RNAP III has not been described as being associated with ssSSc nor is it typically associated with pulmonary arterial hypertension (PAH) \[[@B2], [@B3]\].

2. Case Description {#sec2}
===================

A 59-year-old African American female with a history of hypertension, gastroesophageal reflux disease, and Raynaud\'s phenomenon (RP) initially presented to an outside facility with 6 months of progressive shortness of breath, dry cough, and worsening RP with digital ulceration. At that time, her workup was notable for a CT scan of her chest showing fibrotic interstitial lung disease (ILD) most consistent with a non-specific interstitial pneumonia pattern and right heart catheterization showing pulmonary artery pressures of 80/32 mmHg (mean 47 mmHg), pulmonary capillary wedge pressure of 9 mmHg, cardiac output of 4.91 L/minute, and pulmonary vascular resistance of 619 dyne·second·cm^−5^. Based on these findings, she was started on treatment with sildenafil 40 mg three times daily and mycophenolate mofetil 500 mg daily and referred to our PAH clinic for further evaluation. In clinic, she was noted to have progression of her pulmonary symptoms and dry gangrene (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Given her clinical decline, she was admitted for initiation of epoprostenol as well as further workup for the underlying etiology of her symptoms.

On admission, the physical exam was notable for multiple gangrenous digits, a right fifth digital ulcer, accentuated P2, 2/6 systolic murmur at the right upper sternal border, and coarse crackles bilaterally on lung auscultation. Given the extent of the gangrene, examination of the hands was limited. Her digits did appear slightly puffy; however, there did not appear to be any sclerodactyly or any other skin involvement. Nailfold capillaroscopy done using the ophthalmoscope was notable for capillary dilatations and dropout in the nongangrenous digits. An extensive laboratory workup was completed with pertinent positives including an ANA (1 : 320 nucleolar pattern) and anti-RNAP III (Tables [1](#tab1){ref-type="table"} [](#tab2){ref-type="table"} [](#tab3){ref-type="table"}--[4](#tab4){ref-type="table"}). Notably, there was no evidence of other SSc autoantibodies, antiphospholipid antibodies, or renal involvement. Her initial CK on admission was elevated to 1162; however, it quickly downtrended over the next several days without any targeted treatment and the patient had no weakness noted. It was thought that the elevation in CK was likely secondary from the degree of critical digital ischemia. Further workup included pulmonary function tests showing a restrictive lung defect with an FVC of 2.15 L (64% predicted), FEV1/FVC ratio of 69%, DLCO of 7.98 mL/mmHg·sec (37% predicted), and an FVC/DLCO ratio of 1.7. In addition, an esophagram was done showing mild dilation and dysmotility of the distal esophagus and a cardiac MRI showing no evidence of infiltrative disease. Lastly, a VQ scan revealed a large unmatched perfusion defect of the left base consistent with pulmonary embolism (PE), but this was not felt to be the sole etiology for her PAH. The etiology of her PE was not elucidated at that time. However, her hypercoagulable workup was negative ([Table 2](#tab2){ref-type="table"}) and CT images of her chest, abdomen, pelvis, and head showed no evidence of any malignancy, although it should be noted that she was not up to date on her age appropriate cancer screening including a colonoscopy, pap smear, and mammogram. Further workup was to be pursued as an outpatient given a low suspicion at the time for an underlying malignancy. Given the above findings, she fulfilled the 2013 ACR criteria for a diagnosis of SSc with a score of 12 and she was diagnosed with ssSSc.

For her treatment, she was started on a continuous heparin and epoprostenol infusion which was titrated up to 7 ng·kg^−1^·min^−1^ with further increases as an outpatient. She was continued on sildenafil 40 mg three times daily as well as mycophenolate mofetil, which was increased to 1 g twice daily by discharge. Her pulmonary symptoms significantly improved as did her digital ulceration and pain.

3. Discussion {#sec3}
=============

The patient presented for discussion represents a unique case of anti-RNAP III positive ssSSc. Systemic sclerosis sine scleroderma is a rare subset of scleroderma accounting for approximately 2--9% of SSc patients \[[@B1], [@B4]\]. These patients are noted to have internal organ involvement, laboratory features, and serum autoantibody type similar to those with lcSSc but lack the characteristic skin thickening noted in other forms of SSc. Prior studies have characterized these patients as having predominately pulmonary, gastrointestinal, and peripheral vascular involvement. Notably they often lack renal involvement and may have higher rates of PAH as compared to their lcSSc counterparts \[[@B1], [@B5]\].

Based on a recent multicenter study, serological profiles of patients with ssSSc were similar to those with lcSSc but different from dcSSc with higher rates of anti-centromere antibodies (50% ssSSc versus 12% in dcSSc) and lower rates of anti-topoisomerase I antibodies (16% ssSSc versus 22% dcSSc). Yet, no patients in this cohort presented with anti-RNAP III (0% ssSSc versus 35% dcSSc) \[[@B3]\]. Despite some similarities with our patient\'s presentation to typical ssSSc disease, the major outlier is the anti-RNAP III positivity. Typically, anti-RNAP III is associated with increased risk of developing scleroderma renal crisis, diffuse skin disease, a temporal relationship with malignancy, gastric antral vascular ectasia, myositis, synovitis, and joint contractures, none of which were seen in our patient \[[@B2], [@B6]\]. Other features such as PAH are similarly not common in the anti-RNAP III positive groups as shown in a recent study of 164 patients with PAH related SSc. This study noted that only 9% were anti-RNAP III positive with the larger portion being 37% anti-centromere antibody (ACA) and 24% ANA (anti-nucleolar pattern) \[[@B7]\]. Furthermore, based on a 20-year prospective study, patients with RP, anti-RNAP III positivity, and abnormal nailfold capillaroscopy are 60 times more likely to develop dcSSc versus other forms of SSc \[[@B8]\].

Beyond the phenotypic variation between autoantibody profiles, there is also significant variation of autoantibodies based on ethnicity. This has been highlighted in several prior studies showing that Caucasians typically are positive for anti-RNAP III, ACA, and anti-Pm/Scl, while African Americans have more anti-U3 RNP, anti-U1 RNP, and anti-topoisomerase I \[[@B9]--[@B11]\]. In addition, a prior study of 1432 SSc patients and their autoantibody status showed that only 4% of the anti-RNAP III positive group was African American with the overwhelming majority being Caucasian \[[@B9]\].

In conclusion, to our knowledge, this is the first case in the literature of an ssSSc patient that is anti-RNAP III positive who presented with digital ischemia, PAH, and ILD without the typical features of anti-RNAP III disease. We identified only one other case report of an ssSSc patient that was anti-RNAP III positive. This patient, however, presented with 6 months of symmetric polyarthritis and rapidly progressive renal failure \[[@B12]\].
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###### 

Autoimmune laboratory results.

  Labs                               Value       Normal range
  ---------------------------------- ----------- --------------------------
  ESR                                120 mm/hr   0--29 mm/hr
  CRP                                8.8         1.0--10.0 mg/L
  Creatine kinase                    1162        30--223 U/L
  ANA ratio                          2.85        0.00--0.99
  Nucleolar pattern                  1 : 320     1 : 40
  ANCA myeloperoxidase               \<0.9       0.0--9.0 U/mL
  ANCA proteinase 3                  \<3.5       0.0--3.5 U/mL
  Atypical P-ANCA                    \<1 : 20    Negative \< 1 : 20 titer
  Anti-centromere antibody           \<0.2       0.0--0.9 AI
  Double stranded DNA                1           0--9 IU/mL
  C3 complement                      139         87--200 mg/dL
  C4 complement                      29          19--52 mg/dL
  Anti-Jo-1                          Negative    Negative
  SCL-70 antibody                    Negative    Negative
  SM antibody                        Negative    Negative
  SM/RNP antibodies                  Negative    Negative
  Anti-SSA/SSB antibodies            Negative    Negative
  Anti-RNA polymerase III antibody   33.6        \<20 units/mL
  Anti-Th/To                         Negative    Negative
  Anti-U3RNP                         Negative    Negative
  Anti-U1RNP                         \<20        \<20

ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; ANA: anti-nuclear antibody; ANCA: anti-neutrophil cytoplasmic antibodies.

###### 

Hypercoagulable laboratory results.

  Labs                        Value      Normal range
  --------------------------- ---------- ---------------------
  Anticardiolipin antibody    Negative   Negative
  Factor V Leiden             Normal     Normal
  Homocysteine                12.1       5.0--12.0 *μ*mol/L
  Lupus anticoagulant         Negative   Negative
  Beta-2 glycoprotein 1 IgG   \<9        0--20 GPI IgG units
  Beta-2 glycoprotein 1 IgM   \<9        0--32 GPI IgM units
  Beta-2 glycoprotein 1 IgA   9          0--25 GPI IgA units
  Protein C activity          156        70--130%
  Protein S activity          55         55--123%
  Gamma globulin              2.8        0.50--1.50 g/dL
  Kappa/lambda ratio          1.70       0.26--1.65 ratio
  M spike                     0.0        None

###### 

Other laboratory results.

  Labs                     Value   Normal range
  ------------------------ ------- ------------------------
  White blood cell count   8.2     3.8--10.8  10*E*3/*µ*L
  Hemoglobin               11.2    11.7--15.5 g/dL
  Hematocrit               35.6    35--45%
  MCV                      91.4    80--100 fL
  Platelets                410     140--400  10*E*3/*µ*L
  Sodium                   135     133--146 mmol/L
  Potassium                3.8     3.5--5.3 mmol/L
  Chloride                 101     98--110 mmol/L
  Creatinine               0.44    0.60--1.30 mg/dL
  BUN                      13      7--25 mg/dL
  Glucose                  93      70--100 mg/dL
  Calcium                  10      8.6--10.3 mg/dL
  Total bilirubin          0.3     0--1.5 mg/dL
  Direct bilirubin         0.06    0--0.40 mg/dL
  AST                      24      13--39 U/L
  ALT                      16      7--52 U/L
  Alkaline phosphatase     50      36--125 U/L
  Total protein            7.1     6.4--8.9 g/dL
  Albumin                  3.5     3.5--5.7 g/dL

###### 

Urinalysis.

  Labs               Value      Normal range
  ------------------ ---------- --------------
  Specific gravity   1.013      1.005--1.035
  pH                 6          5--8
  Protein            Negative   Negative
  Glucose            Negative   Negative
  Blood              Negative   Negative
  Nitrite            Negative   Negative
  Leukocytes         Negative   Negative
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